Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
← catalyst calendarNCT07645820 · readout in 225 d
Sponsored by Castle Biosciences Incorporated (industry) · CSTL — their whole pipeline →. With SciBase AB.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
450estimated
Sites
4
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-29 | estimated | When the study began enrolling |
| Primary completion | 2027-04-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-12-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atopic Dermatitis
Intervention
- Device: Nevisense electrical impedance spectroscopy
Primary outcomes
what the primary-completion date above is the date OFRelationship between skin measurements and subsequent atopic dermatitis flares
measured Measurements taken over 90 days, 5 days a week
Develop and validate an algorithm using Nevisense Go EIS
measured From enrollment until end of treatment at 90 days.
Permalink · CSTL's whole pipeline · Catalyst calendar · Every registered study · What changed